|Flamel and GlaxcoSmithKline Agree to Supply Agreement; AstraZeneca, Forest Labs Enter Superbug Combo.|
|By Staff and Wire Reports|
|Tuesday, 18 October 2011 18:41|
Flamel Technologies (NASDAQ:FLML) announced it has entered into a multi-year supply agreement with GlaxoSmithKline (NYSE:GSK) for the production of Coreg CR microparticles.
Flamel Technologies is the sole supplier of Coreg CR microparticles for GlaxoSmithKline. Under the agreement, Flamel will receive guaranteed minimum payments to supply Coreg CR microparticles over a period of several years. The agreement defines the manufacturing relationship between the two companies following the expiration of the previous supply agreement on December 31, 2010. Pursuant to the agreement, Flamel received a payment of EUR1.3 MM during the third quarter and anticipates a further EUR1.3 MM payment to be paid in the next ten days, as well as the higher margin on all product produced by Flamel since January 1, 2011.
Stephen H. Willard, Flamel's chief executive officer, commented, "We welcome the conclusion of this agreement with GSK. The new supply agreement provides Flamel and its shareholders with higher margins and greater certainty. We believe that this agreement further strengthens our ability to develop both of our best-in-class drug delivery platforms."
AstraZeneca PLC (NYSE:AZN) and U.S. partner Forest Laboratories Inc. (NYSE:FRX) said they plan a late-stage clinical trial program to investigate a combination antibiotic against superbug infections.
The two drug makers will enter ceftazidime/avibactam into five Phase 3 trials to show the combination is an effective and well-tolerated treatment for patients with Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections.
"This combination of a broad-spectrum cephalosporin and a novel beta-lactamase inhibitor has the potential to be effective against bacteria that would otherwise be resistant to antibiotics in patients suffering from serious and potentially life-threatening infections," Marco Taglietti, president of Forest Research Institute, said in a statement.
The partners said they aimed to submit ceftazidime/avibactam for regulatory approval in 2014.
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today that the company is scheduled to present at the 18th Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City on Friday, October 21.
Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, commented on the decision issued today by the European Court of Justice decision in the matter of Oliver Brüstle v Greenpeace.
AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging in vitro diagnostic company, will host a conference call to report on its progress with AppyScore™, a rule out test designed to aid in managing the large numbers of patients who enter the emergency rooms of hospitals every year complaining of abdominal pain suspicious for appendicitis by helping to identify those who are at low to moderate risk.
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, the Netherlands.
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2011.
China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the board increased the number of directors on the board of directors to five at its annual board meeting and appointed Mr. Zack Zibing Pan to its Board of Directors, effective October 15, 2011.
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Roberto Romero, M.D., chief of the Perinatology Research Branch of the Division of Intramural Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), of the National Institutes of Health (NIH), was awarded the 2011 John Dingell Hero for Babies Award by the March of Dimes Michigan Chapter.
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that Ana I. Stancic, C.P.A., M.B.A., current Senior Vice President, Finance and Chief Financial Officer, has been promoted to Chief Operating Officer, Principal Executive Officer and Executive Vice President, effective immediately.
Express Scripts (Nasdaq: ESRX), one of the largest pharmacy benefit management companies in North America, announced today its intention to release its third quarter earnings on Tuesday, October 25, 2011 after the market closes and will hold its quarterly conference call to discuss third quarter results on Wednesday, October 26, 2011, at 9:30 a.m. Eastern Time (8:30 a.m. Central Time).
GenVec, Inc. (NASDAQ: GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a Company overview highlighting recent developments at the 2011 10th Annual BIO Investor Forum on Tuesday, October 25, 2011 at 3:00 p.m. PDT at the Palace Hotel in San Francisco.
Given Imaging Ltd. (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced that results of a study published in the September issue of Inflammatory Bowel Disease showed that physicians changed how they treated the majority of their symptomatic IBD cases, after performing PillCam capsule endoscopy.
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion.
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2011.
Life Technologies Corporation (Nasdaq: LIFE) today announced that Jonathan Rothberg, CEO and founder of Ion Torrent, is a runner-up in this year's Wall Street Journal Technology Innovation Awards for the Ion Personal Genome Machine (PGM™), which "promises to sequence DNA more quickly and at a lower cost than other sequencing technologies," the awards committee said.
Marijuana, Inc. (PINKSHEETS: HEMP) announced today their retention of EJM as public relations firm. EJM Advisors' role is to expand the visibility of HEMP's capabilities through mainstream press coverage of its role in the marijuana industry.
Micro Imaging Technology, Inc. (OTCBB: MMTC) (OTCQB: MMTC) announced today the volume availability in early 2012 of the MIT 1000A (Figure 1).
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that more than 20 data presentations from the company’s growing multiple sclerosis (MS) portfolio will be showcased at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS 2011).
Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, announced today that it has engaged Sherb & Co., LLP ("Sherb & Co.") as its new independent auditor.
Vasomedical, Inc. (OTC: VASO.PK), a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, today reported financial results for the three months ended August 31, 2011.
VisualMED Clinical Solutions Corp. (PINKSHEETS: VMCS) (FRANKFURT: VA6) is pleased to be able to announce today that it expects revenues for the first quarter of fiscal 2012 to be between $320,000 and $400,000.